Advertisement
U.S. markets closed
Advertisement

Ardelyx, Inc. (ARDX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
4.3700+0.2800 (+6.85%)
At close: 04:00PM EST
4.3500 -0.02 (-0.46%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
Previous Close4.0900
Open4.1100
Bid4.3800 x 1400
Ask4.3500 x 3200
Day's Range4.1100 - 4.4000
52 Week Range1.6800 - 5.1250
Volume4,999,878
Avg. Volume6,667,322
Market Cap1.014B
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings DateOct 31, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.31
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARDX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ardelyx, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Ardelyx, Inc. Reports Employment Inducement Grants

    WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on November 20, 2023, the compensation committee of the company’s board of directors granted fourteen new non-executive employees options to purchase an aggregate of 221,805 shares of the company’s common stock, and granted sixte

  • InvestorPlace

    7 Penny Stocks You’ll Regret Not Buying Soon: November 2023

    In the ever-evolving investment landscape, penny stocks to buy emerge as the thrill-seekers’ darlings. Known for their high-risk, high-reward nature, these stocks attract investors with their low share prices and the promise of substantial gains. Furthermore, these stocks mirror current growth trends in various industries, demonstrating resilience in a tumultuous economy. Among them, certain standouts are well-positioned to evolve amidst rising interest rates. The appeal of these stocks extends

  • GlobeNewswire

    Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

    WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Ardelyx management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 2:30 p.m. E.T. in New York City. To access the live webcast of Ardelyx's session, p